Myopia in Pune Is Getting Worse
Faster Than It Should

Myopia management is a relatively recent clinical specialisation - the clinical trials for low-dose atropine and orthokeratology were largely published in the 2010s, and widespread clinical adoption has been gradual. General ophthalmologists and optometrists primarily trained before this evidence base matured may not routinely offer or discuss these interventions. This is a gap in how myopia care is delivered, not a judgement on your doctor. If your child's prescription is progressing by 0.50 D or more annually, a dedicated myopia management consultation is warranted regardless of what prior practitioners have or haven't raised.

It depends on age and trajectory. A -1.00 D prescription at age 8 with 0.75 D progression in the past year is a higher-risk situation than a -2.50 D prescription at age 15 that has been stable for 18 months. Progression rate and age matter more than the absolute prescription level in deciding whether to start management. A child who is -1.00 D at age 8 with rapid progression and both parents myopic is an ideal candidate for early management - catching it here, rather than at -4.00 D at age 13, is the point of the intervention.

The concern about atropine side effects relates to the 1% concentration used in older protocols. Low-dose atropine (0.025% or 0.05%) - the current standard for myopia management - has a significantly different side-effect profile. In the LAMP trial, which studied 0.05% and 0.025% concentrations specifically, adverse effects were minimal: very mild light sensitivity and negligible near blur. The 0.025% dose in particular had virtually no measurable side effects while still showing meaningful slowing of progression. We advise on concentration, formulation, and monitoring, and we coordinate with your optometrist or ophthalmologist for any refraction monitoring required.

Orthokeratology lens fitting itself requires an in-person visit with corneal topography equipment - that part cannot be done via telehealth. What we can do via telehealth: a full myopia management assessment, review of your child's progression history and risk factors, clinical recommendation for whether ortho-k is appropriate, and guidance on what to look for in an ortho-k fitting provider in Pune. We can advise on practitioners in the Baner/Pune area who offer ortho-k. For the ongoing monitoring component - assessing whether the management is working based on progression data - that can be done by us in coordination with the local fitting provider.

Yes, for two reasons. First, myopia progression in Indian populations often continues until the mid-20s - it is not always complete at age 16. If her prescription is still changing, management can limit further increase. Second, the rationale for management is not only prescription control but reducing long-term risk: every dioptre of myopia above -3.00 D multiplies risk of retinal pathology, and management can cap that trajectory. Low-dose atropine is reasonable to consider even at -5.50 D if progression is ongoing. At that level, we would also discuss the importance of annual retinal examination with a Pune ophthalmologist regardless of what management is or isn't undertaken.

The protective threshold in the literature is approximately 80–90 minutes of bright outdoor light daily. The mechanism is retinal dopamine triggered by light intensities above 10,000 lux - which indoor environments, even well-lit ones, don't approach. For Hinjewadi families in high-rise buildings with limited outdoor space, this is genuinely challenging. Practical options: morning school drop-off on foot where possible, evening play time even in the building compound, weekend park visits, and ensuring the child's classroom or study position has maximum natural light. Outdoor time is not a substitute for active management in a high-risk child, but it is a meaningful additive intervention - particularly during the primary school years when the biology is most responsive.